ºÚÁÏÍø

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

When I realized how under fueled I was, I knew I had to rethink my eating habits.

This year has been a major year in the field of Alzheimer disease (AD), with several promising therapies moving forward and the first FDA approval in almost 2 decades.

Air Force veteran Ally Schroeder, 27, will graduate in May from ºÚÁÏÍø with a bachelor’s degree in nutrition sciences. She has been paying for her tuition and housing through the G.I. Bill, which has provided money toward schooling or job training to service members since the 1940s.

It’s called the Chambers-Grundy Center for Transformative Neuroscience at ºÚÁÏÍø, and the adjective in the name says it all.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.

The pandemic put a lot of people out of work, which meant a lot of people did not know where their next meal would come from. Now that more people are back to work, inflation means food is costing a lot.

Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.

The cause of Alzheimer’s was supposedly simple.

Alzheimer’s treatments seemed unlikely just a few months ago.

A week ago, Brigham and Women's Hospital announced it would spearhead the first human trial of a nasal spray vaccine as a protection against Alzheimer's disease, formulated to prevent or delay the progression of the disease.

Last week, Brigham and Women's Hospital announced that it would pioneer a trial using a spray drug for Alzheimer's disease.